Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the Phase 1 clinical trial of its MASP-3 inhibitor OMS906. The ongoing trial is designed as a…
Read More
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the completion of its business combination with Arya Sciences Acquisition Corp III (Nasdaq: ARYA; or “Arya III”), a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. The combined company, Nautilus Biotechnology, Inc. (“Nautilus”), will commence trading shares of its common stock under…
Read More
Our June faculty spotlight is on Dr. Steven Disharoon, clinical assistant professor in the Division of General Internal Medicine. Dr. Disharoon received his medical degree from Virginia Commonwealth University, and completed his internship and residency at Oregon Health & Science University. Wanting to pursue a career where he could have involvement in education, quality improvement, and be able to work…
Read More
UW Medicine was one of the clinical trial sites for aducanumab, a drug approved by the FDA to slow the progression of Alzheimer’s disease. The drug created by Biogen is not a cure and it’s not for everyone. But researchers say it marks a new era in Alzheimer’s research, with more potential treatments in the pipeline. Around the country, the…
Read More
Icosavax, Inc. today announced the first subjects have been dosed with IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain (RBD), in a Phase 1/2 clinical trial. As previously announced, the Phase 1/2 trial is being funded by the Bill & Melinda Gates Foundation. Amgen is manufacturing a key intermediate, and Seqirus is providing its proprietary MF59® adjuvant for…
Read More
Washington State University researchers hope that their tool to rapidly grow cancer-killing T cells can someday make a difference in fighting the disease. Under the guidance of Professor Bernard Van Wie, graduate students Kitana Kaiphanliam and Brenden Fraser-Hevlin are working to commercialize a bioreactor that is able to grow 25 times more of the valuable T cells than current technology…
Read More
After more than 30 years at Fred Hutchinson Cancer Research Center, primarily studying prostate cancer genetics, risk factors and treatment outcomes, faculty member Dr. Janet Stanford has retired. She now holds the title of professor emeritus. Over her career, Stanford has made an impact both through her scientific discoveries and her leadership, said longtime research colleague Dr. Elaine Ostrander of the National Human Genome…
Read More

BBI Faculty Conversations – Dr. Sarah Leary

Today’s installment is with BBI member Dr. Sarah Leary. Dr. Leary is an attending physician in the Cancer and Blood Disorders Center at Seattle Children’s Hospital and Associate Professor of Pediatrics at the University of Washington School of Medicine. BBI: To start, could you tell us a little bit about the focus of your work, and how it relates to…
Read More
IPD researchers together with collaborators at the National Institutes of Health have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The lead vaccine candidate has entered human clinical testing at the NIH. If it proves safe and effective, these next-generation influenza vaccines may replace current seasonal options by providing protection against…
Read More
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders, today announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. These patients…
Read More